<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30310523</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1837-9664</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <Issue>19</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Journal of Cancer</Title>                <ISOAbbreviation>J Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.</ArticleTitle>            <Pagination>                <MedlinePgn>3640-3646</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.7150/jca.26825</ELocationID>            <Abstract>                <AbstractText><b>Background:</b> Bone is the most common site of metastasis of breast cancer. Biological mechanisms of metastasis to bone may be different from mechanisms of metastasis to non-bone sites, and identification of distinct signaling pathways and somatic mutations may provide insights on biology and rational targets for treatment and prevention of bone metastasis. The aims of this study were to compare and contrast somatic mutations, clinicopathologic characteristics, and survival in breast cancer patients with bone-only versus non-bone sites of first metastasis. <b>Methods:</b> Primary tumor samples were collected before treatment from 389 patients with untreated primary breast cancer and distant metastasis at diagnosis. In each sample, 46 or 50 cancer-related genes were analyzed for mutations by AmpliSeq Ion Torrent next-generation sequencing. Fisher's exact test was used to identify somatic mutations associated with bone-only first metastasis. Logistic regression models were used to identify differences in detected somatic mutations, clinicopathologic characteristics, and survival between patients with bone-only first metastasis and patients with first metastasis in non-bone sites only (&quot;other-only first metastasis&quot;). <b>Results:</b> Among the 389 patients, 72 (18.5%) had bone-only first metastasis, 223 (57.3%) had other-only first metastasis, and 94 (24.2%) had first metastasis in both bone and non-bone sites. The most commonly mutated genes were <i>TP53</i> (N=103), <i>PIK3CA</i> (N=79), <i>AKT</i> (N=13), and <i>PTEN</i> (N=2). Compared to patients with other-only first metastasis, patients with bone-only first metastasis had higher rates of hormone-receptor-positive disease, non-triple-negative subtype, and lower grade (grade 1 or 2; Nottingham grading system) (all three comparisons, <i>p</i>&lt;0.001); had a lower ratio of cases of invasive ductal carcinoma to cases of invasive lobular carcinoma (<i>p</i>=0.002); and tended to have a higher 5-year overall survival (OS) rate (78.2% [95% confidence interval (CI), 68.6%-89.0%] vs 55.0% [95% CI, 48.1%-62.9%]; <i>p</i>=0.051). However, in the subgroup of patients with <i>TP53</i> mutation and in the subgroup of patients with <i>PIK3CA</i> mutation, OS did not differ between patients with bone-only and other-only first metastasis (<i>p</i>=0.49 and <i>p</i>=0.68, respectively). In univariate analysis, the rate of <i>TP53</i> mutation tended to be lower in patients with bone-only first metastasis than in those with other-only first metastasis (15.3% vs 29.1%; <i>p</i>=0.051). In multivariate analysis, <i>TP53</i> mutation was not significantly associated with site of first metastasis (<i>p</i>=0.54) but was significantly associated with hormone-receptor-negative disease (<i>p</i>&lt;0.001). <b>Conclusions:</b> We did not find associations between somatic mutations and bone-only first metastasis in patients with untreated breast cancer. Patients with bone-only first metastasis tend to have longer OS than patients with other-only first metastasis. More comprehensive molecular analysis may be needed to further understand the factors associated with bone-only metastatic disease in breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kono</LastName>                    <ForeName>Miho</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fujii</LastName>                    <ForeName>Takeo</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matsuda</LastName>                    <ForeName>Naoko</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harano</LastName>                    <ForeName>Kenichi</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Huiqin</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wathoo</LastName>                    <ForeName>Chetna</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Sheikh Khalifa Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Joon</LastName>                    <ForeName>Aron Y</ForeName>                    <Initials>AY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tripathy</LastName>                    <ForeName>Debu</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Meric-Bernstam</LastName>                    <ForeName>Funda</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Sheikh Khalifa Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Investigational Cancer Therapeutics (Phase I Trials Department), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ueno</LastName>                    <ForeName>Naoto T</ForeName>                    <Initials>NT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P30 CA016672</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>UL1 TR000371</GrantID>                    <Acronym>TR</Acronym>                    <Agency>NCATS NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>J Cancer</MedlineTA>            <NlmUniqueID>101535920</NlmUniqueID>            <ISSNLinking>1837-9664</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Apr;150(3):547-57</RefSource>                <PMID Version="1">25820592</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 May 20;24(15):2261-7</RefSource>                <PMID Version="1">16636340</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Investig Drugs. 2012 Jun;21(6):785-95</RefSource>                <PMID Version="1">22500564</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2016 Dec 27;13(12):e1002201</RefSource>                <PMID Version="1">28027327</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Care. 2004 Feb;42(2):164-75</RefSource>                <PMID Version="1">14734954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2012 Jun 01;11(6):479-97</RefSource>                <PMID Version="1">22653217</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2010 Jul;17(7):1862-9</RefSource>                <PMID Version="1">20162457</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011;13(6):R127</RefSource>                <PMID Version="1">22151997</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2014 Nov;15(12):1397-406</RefSource>                <PMID Version="1">25439694</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2017 Apr 9;8(6):1045-1052</RefSource>                <PMID Version="1">28529618</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Oct 1;68(19):7795-802</RefSource>                <PMID Version="1">18829534</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 1998;77(2):336-40</RefSource>                <PMID Version="1">9461007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 1980;Suppl 1:59-62</RefSource>                <PMID Version="1">7318870</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2009 Jul 7;16(1):67-78</RefSource>                <PMID Version="1">19573813</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2014 Jul 1;74(13):3399-407</RefSource>                <PMID Version="1">24924774</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 1987 Jan;55(1):61-6</RefSource>                <PMID Version="1">3814476</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Jun;145(2):411-8</RefSource>                <PMID Version="1">24728613</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Jan;131(1):231-8</RefSource>                <PMID Version="1">21842243</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Apr 04;486(7403):395-9</RefSource>                <PMID Version="1">22495314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4</RefSource>                <PMID Version="1">16813731</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2005 Oct 15;96(3):484-9</RefSource>                <PMID Version="1">16052475</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource>                <PMID Version="1">23000897</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Diagn. 2013 Sep;15(5):607-22</RefSource>                <PMID Version="1">23810757</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Pathol Lab Med. 2010 Jun;134(6):907-22</RefSource>                <PMID Version="1">20524868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2010 Dec;101(12):2670-5</RefSource>                <PMID Version="1">20946121</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Nucl Med. 1984 Oct;14(4):277-86</RefSource>                <PMID Version="1">6387915</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2013 Jun 19;105(12):908-16</RefSource>                <PMID Version="1">23682134</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2003 Aug 18;89(4):660-5</RefSource>                <PMID Version="1">12915874</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2001 Jun;27(3):165-76</RefSource>                <PMID Version="1">11417967</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2003 Mar;78(1):105-18</RefSource>                <PMID Version="1">12611463</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2004;(2):CD004721</RefSource>                <PMID Version="1">15106258</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2011 Jun;10(6):1093-101</RefSource>                <PMID Version="1">21490305</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2014 Feb;27(2):314-27</RefSource>                <PMID Version="1">23907151</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Nov 22;7(47):76362-76373</RefSource>                <PMID Version="1">27806348</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">PIK3CA</Keyword>            <Keyword MajorTopicYN="N">TP53</Keyword>            <Keyword MajorTopicYN="N">bone metastasis</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">prognostic factor</Keyword>            <Keyword MajorTopicYN="N">somatic mutation</Keyword>        </KeywordList>        <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30310523</ArticleId>            <ArticleId IdType="doi">10.7150/jca.26825</ArticleId>            <ArticleId IdType="pii">jcav09p3640</ArticleId>            <ArticleId IdType="pmc">PMC6171013</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>